Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.
Saved in:
| Title: | Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial. |
|---|---|
| Authors: | Seefat RL; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Vliek SB; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands., de Jong VMT; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Balduzzi S; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands., Mandjes IA; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands., Retèl VP; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands., Eekhout I; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands., Delfos M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Schot M; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Holtkamp MJ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., van Rosmalen MM; Department of Medical Oncology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands., Leeneman B; Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands., Blommestein H; Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Princess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands., Rosenberg EH; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Nederlof PM; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Chan TWS; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., van Rhenen A; Department of Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands., Wondergem MJ; Department of Haematology, Amsterdam University Medical Center, Amsterdam, Netherlands., Schaap NPM; Department of Haematology, Radboud University Medical Centre, Nijmegen, Netherlands., Snijders TJF; Department of Haematology, Medisch Spectrum Twente, Enschede, Netherlands., Van der Poel MWM; Department of Haematology, Maastricht University Medical Center, Maastricht, Netherlands., Plattel WJ; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., van Werkhoven E; Department of Medical Oncology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands., van Tinteren H; Princess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands., Smidt ML; Department of Surgery, Maastricht University Medical Center, Maastricht, Netherlands., Wesseling J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Jonkers J; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands., Rottenberg S; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Switzerland., Vrancken Peeters MTFD; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Surgery, Amsterdam University Medical Center, Amsterdam, Netherlands., Voermans C; Department of Haematology, Amsterdam University Medical Center, Amsterdam, Netherlands; Department of Research, Sanquin Blood Supply Foundation, Amsterdam, Netherlands; Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., Maduro JH; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands., Schroder CP; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands., Kuip EJM; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands., Gonçalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France., Nuver J; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Wymenga ANM; Department of Medical Oncology, Medisch Spectrum Twente, Enschede, Netherlands., Bijlsma RM; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands., van der Wall E; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands., Konings IRHM; Department of Medical Oncology, Amsterdam University Medical Center, Amsterdam, Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, Netherlands., Jongen-Lavrencic M; Department of Haematology, Erasmus University Medical Center, Rotterdam, Netherlands., Jager A; Department of Medical Oncology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands., Linn SC; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. Electronic address: s.linn@nki.nl. |
| Source: | The Lancet. Oncology [Lancet Oncol] 2026 Jul; Vol. 27 (7), pp. 795-807. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study |
| Journal Info: | Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42372741 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Seefat+RL%22">Seefat RL</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Vliek+SB%22">Vliek SB</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Jong+VMT%22">de Jong VMT</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Balduzzi+S%22">Balduzzi S</searchLink>; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Mandjes+IA%22">Mandjes IA</searchLink>; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Retèl+VP%22">Retèl VP</searchLink>; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Eekhout+I%22">Eekhout I</searchLink>; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Delfos+M%22">Delfos M</searchLink>; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Schot+M%22">Schot M</searchLink>; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Holtkamp+MJ%22">Holtkamp MJ</searchLink>; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Rosmalen+MM%22">van Rosmalen MM</searchLink>; Department of Medical Oncology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Leeneman+B%22">Leeneman B</searchLink>; Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Blommestein+H%22">Blommestein H</searchLink>; Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Huitema+ADR%22">Huitema ADR</searchLink>; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Princess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Rosenberg+EH%22">Rosenberg EH</searchLink>; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Nederlof+PM%22">Nederlof PM</searchLink>; Department of Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Chan+TWS%22">Chan TWS</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Rhenen+A%22">van Rhenen A</searchLink>; Department of Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Wondergem+MJ%22">Wondergem MJ</searchLink>; Department of Haematology, Amsterdam University Medical Center, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Schaap+NPM%22">Schaap NPM</searchLink>; Department of Haematology, Radboud University Medical Centre, Nijmegen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Snijders+TJF%22">Snijders TJF</searchLink>; Department of Haematology, Medisch Spectrum Twente, Enschede, Netherlands.<br /><searchLink fieldCode="AU" term="%22Van+der+Poel+MWM%22">Van der Poel MWM</searchLink>; Department of Haematology, Maastricht University Medical Center, Maastricht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Plattel+WJ%22">Plattel WJ</searchLink>; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Werkhoven+E%22">van Werkhoven E</searchLink>; Department of Medical Oncology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Tinteren+H%22">van Tinteren H</searchLink>; Princess Máxima Centre for Paediatric Oncology, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Smidt+ML%22">Smidt ML</searchLink>; Department of Surgery, Maastricht University Medical Center, Maastricht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Wesseling+J%22">Wesseling J</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Jonkers+J%22">Jonkers J</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Rottenberg+S%22">Rottenberg S</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Switzerland.<br /><searchLink fieldCode="AU" term="%22Vrancken+Peeters+MTFD%22">Vrancken Peeters MTFD</searchLink>; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Surgery, Amsterdam University Medical Center, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Voermans+C%22">Voermans C</searchLink>; Department of Haematology, Amsterdam University Medical Center, Amsterdam, Netherlands; Department of Research, Sanquin Blood Supply Foundation, Amsterdam, Netherlands; Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Maduro+JH%22">Maduro JH</searchLink>; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Kroep+JR%22">Kroep JR</searchLink>; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.<br /><searchLink fieldCode="AU" term="%22Schroder+CP%22">Schroder CP</searchLink>; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Kuip+EJM%22">Kuip EJM</searchLink>; Department of Medical Oncology, Radboud University Medical Center Nijmegen, Nijmegen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Gonçalves+A%22">Gonçalves A</searchLink>; Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.<br /><searchLink fieldCode="AU" term="%22Nuver+J%22">Nuver J</searchLink>; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Wymenga+ANM%22">Wymenga ANM</searchLink>; Department of Medical Oncology, Medisch Spectrum Twente, Enschede, Netherlands.<br /><searchLink fieldCode="AU" term="%22Bijlsma+RM%22">Bijlsma RM</searchLink>; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Wall+E%22">van der Wall E</searchLink>; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Konings+IRHM%22">Konings IRHM</searchLink>; Department of Medical Oncology, Amsterdam University Medical Center, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Tjan-Heijnen+VCG%22">Tjan-Heijnen VCG</searchLink>; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Jongen-Lavrencic+M%22">Jongen-Lavrencic M</searchLink>; Department of Haematology, Erasmus University Medical Center, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Jager+A%22">Jager A</searchLink>; Department of Medical Oncology, Erasmus University Medical Center Cancer Institute, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Linn+SC%22">Linn SC</searchLink>; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands; Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands. Electronic address: s.linn@nki.nl. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2026 Jul; Vol. 27 (7), pp. 795-807. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42372741 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S1470-2045(26)00131-2 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 795 Titles: – TitleFull: Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Seefat RL – PersonEntity: Name: NameFull: Vliek SB – PersonEntity: Name: NameFull: de Jong VMT – PersonEntity: Name: NameFull: Balduzzi S – PersonEntity: Name: NameFull: Mandjes IA – PersonEntity: Name: NameFull: Retèl VP – PersonEntity: Name: NameFull: Eekhout I – PersonEntity: Name: NameFull: Delfos M – PersonEntity: Name: NameFull: Schot M – PersonEntity: Name: NameFull: Holtkamp MJ – PersonEntity: Name: NameFull: van Rosmalen MM – PersonEntity: Name: NameFull: Leeneman B – PersonEntity: Name: NameFull: Blommestein H – PersonEntity: Name: NameFull: Huitema ADR – PersonEntity: Name: NameFull: Rosenberg EH – PersonEntity: Name: NameFull: Nederlof PM – PersonEntity: Name: NameFull: Chan TWS – PersonEntity: Name: NameFull: van Rhenen A – PersonEntity: Name: NameFull: Wondergem MJ – PersonEntity: Name: NameFull: Schaap NPM – PersonEntity: Name: NameFull: Snijders TJF – PersonEntity: Name: NameFull: Van der Poel MWM – PersonEntity: Name: NameFull: Plattel WJ – PersonEntity: Name: NameFull: van Werkhoven E – PersonEntity: Name: NameFull: van Tinteren H – PersonEntity: Name: NameFull: Smidt ML – PersonEntity: Name: NameFull: Wesseling J – PersonEntity: Name: NameFull: Jonkers J – PersonEntity: Name: NameFull: Rottenberg S – PersonEntity: Name: NameFull: Vrancken Peeters MTFD – PersonEntity: Name: NameFull: Voermans C – PersonEntity: Name: NameFull: Maduro JH – PersonEntity: Name: NameFull: Kroep JR – PersonEntity: Name: NameFull: Schroder CP – PersonEntity: Name: NameFull: Kuip EJM – PersonEntity: Name: NameFull: Gonçalves A – PersonEntity: Name: NameFull: Nuver J – PersonEntity: Name: NameFull: Wymenga ANM – PersonEntity: Name: NameFull: Bijlsma RM – PersonEntity: Name: NameFull: van der Wall E – PersonEntity: Name: NameFull: Konings IRHM – PersonEntity: Name: NameFull: Tjan-Heijnen VCG – PersonEntity: Name: NameFull: Jongen-Lavrencic M – PersonEntity: Name: NameFull: Jager A – PersonEntity: Name: NameFull: Linn SC IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: 2026 Jul Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1474-5488 Numbering: – Type: volume Value: 27 – Type: issue Value: 7 Titles: – TitleFull: The Lancet. Oncology Type: main |
| ResultId | 1 |
